Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Tarassishin, Leonid ^a   Casper, Diana ^a   Lee, Sunhee C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOCORTIN 2; MESSENGER RNA; MICRORNA; NIGERICIN; SMALL INTERFERING RNA; STAT3 PROTEIN;

ADULT; AGED; ANGIOGENESIS ASSAY; ARTICLE; ASTROCYTE; BIOASSAY; CELL ACTIVATION; CELL CULTURE; CHILD; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE REPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INNATE IMMUNITY; MACROPHAGE; MALE; MICROGLIA; NEUROTOXICITY; NEUROTOXICITY ASSAY; PHENOTYPE; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; UPREGULATION; WESTERN BLOTTING; BRAIN; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

AGED; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 84904674815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103432     Document Type: Article

References (87)

1. Sul J, Fine HA (2010) Malignant gliomas: new translational therapies. Mt Sinai J Med, 77: 655-666.
2. Mitchell DA, Sampson JH (2009) Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics, 6: 527-538.
3. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol, 20: 267-275.
4. Heimberger AB, Sampson JH (2011) Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol, 13: 3-13.
5. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, et al. (2009) Immunotherapeutic approaches for glioma. Crit Rev Immunol, 29: 1-42.
6. Johnson LA, Sampson JH (2010) Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep, 10: 259-266.
7. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell, 124: 783-801. (Pubitemid 43261452)
8. Tarassishin L, Bauman A, Suh HS, Lee SC (2013) Anti-Viral and Anti-Inflammatory Mechanisms of the Innate Immune Transcription Factor Interferon Regulatory Factor 3: Relevance to Human CNS Diseases. J Neuroimmune Pharmacol, 8: 132-144.
9. Yang I, Han SJ, Kaur G, Crane C, Parsa AT (2010) The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci, 17: 6-10.
10. Lee SC (2012) Microglia and innate immunity in neuroAIDS. In: Gendelman HE, Grant I, Everall IP, Fox HS, Gelbard HA, et al., editors. The neurology of AIDS. Oxford University Press, 109-118.
11. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia, 59: 1169-1180.
12. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, et al. (2012) The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol, 180: 2108-2119.
13. Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, et al. (2013) The role of IL-1beta in the early tumor cell-induced angiogenic response. J Immunol, 190: 3500-3509.
14. Tarassishin L, Lim J, Weatherly DB, Angeletti RH, Lee SC (2014) Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. J Proteomics, 99C: 152-168.
15. Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol, 13: 343-351.
16. Dunn JH, Ellis LZ, Fujita M (2012) Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett, 314: 24-33.
17. Dinarello CA (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev, 29: 317-329.
18. Basu A, Krady JK, Levison SW (2004) Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res, 78: 151-156. (Pubitemid 39313786)
19. Basu A, Krady JK, O'Malley M, Styren SD, DeKosky ST, et al. (2002) The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci, 22: 6071-6082. (Pubitemid 35387650)
20. Thornton P, Pinteaux E, Gibson RM, Allan SM, Rothwell NJ (2006) Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J Neurochem, 98: 258-266. (Pubitemid 43882950)
21. Pinteaux E, Rothwell NJ, Boutin H (2006) Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia, 53: 551-556.
22. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC (1999) Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia, 28: 114-127. (Pubitemid 29530610)
23. Lee SC, Dickson DW, Brosnan CF (1995) Interleukin-1, nitric oxide and reactive astrocytes. Brain, Behavior, and Immunity, 9: 345-354. (Pubitemid 26039773)
24. Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, et al. (2007) Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma 15. Proc Natl Acad Sci U S A, 104: 3466-3471. (Pubitemid 46364182)
25. Suh HS, Zhao ML, Derico L, Choi N, Lee SC (2013) Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators. J Neuroinflammation, 10: 37.
26. Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh HS, et al. (2011) Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia, 59: 1911-1922.
27. Tarassishin L, Lee SC (2013) Interferon regulatory factor 3 alters glioma inflammatory and invasive properties. J Neurooncol, 113: 185-194.
28. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, et al. (2011) Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A, 108: 4908-4913.
29. Tili E, Croce CM, Michaille JJ (2009) miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol, 28: 264-284.
30. Lages E, Guttin A, El AM, Ramus C, Ipas H, et al. (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS ONE, 6: e20600.
31. Li N, Grivennikov SI, Karin M (2011) The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell, 19: 429-431.
32. Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res, 6: 675-684.
33. Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G, et al. (2011) SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol, 122: 241-251.
34. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, et al. (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest, 123: 1580-1589.
35. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med, 206: 1457-1464.
36. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, et al. (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med, 19: 57-64.
37. Tribius S, Pidel A, Casper D (2001) ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys, 50: 511-523. (Pubitemid 32472281)
38. Lee SC, Liu W, Brosnan CF, Dickson DW (1992) Characterization of human fetal dissociated CNS cultures with an emphasis on microglia. Lab Invest, 67: 465-475.
39. Tarassishin L, Suh HS, Lee SC (2014) LPS and IL-1 differential activate mouse and human astrocytes: role of CD14. Glia, 62: 999-1013.
40. Liu J, Zhao ML, Brosnan CF, Lee SC (1996) Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1b and IL-1 receptor antagonist. J Immunol, 157: 3569-3576. (Pubitemid 126449171)
41. Schneider KS, Thomas CJ, Gross O (2013) Inflammasome activation and inhibition in primary murine bone marrow-derived cells, and assays for IL-1alpha, IL-1beta, and caspase-1. Methods Mol Biol, 1040: 117-135.
42. Lutz SE, Gonzalez-Fernandez E, Ventura JC, Perez-Samartin A, Tarassishin L, et al. (2013) Contribution of pannexin1 to experimental autoimmune encephalomyelitis. PLoS ONE, 8: e66657.
43. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, et al. (2011) Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol, 187: 613-617.
44. Tarassishin L, Suh HS, Lee SC (2011) Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. J Neuroinflammation, 8: 187.
45. Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses 17. Nat Immunol, 13: 343-351.
46. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes: differential induction by LPS and IL-1β. J Immunol, 150: 2659-2667. (Pubitemid 23127515)
47. Strowig T, Henao-Mejia J, Elinav E, Flavell R (2012) Inflammasomes in health and disease. Nature, 481: 278-286.
48. Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, et al. (2012) The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol, 2012: 406273.
49. Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, et al. (2011) Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci, 31: 14346-14360.
50. Swisher JF, Burton N, Bacot SM, Vogel SN, Feldman GM (2010) Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood, 115: 549-558.
51. Swisher JF, Khatri U, Feldman GM (2007) Annexin A2 is a soluble mediator of macrophage activation. J Leukoc Biol, 82: 1174-1184. (Pubitemid 350133515)
52. Scharf B, Clement CC, Wu XX, Morozova K, Zanolini D, et al. (2012) Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris. Nat Commun, 3: 755.
53. Wanet A, Tacheny A, Arnould T, Renard P (2012) miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res, 40: 4742-4753.
54. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature, 463: 318-325.
55. Lu T, Tian L, Han Y, Vogelbaum M, Stark GR (2007) Dose-dependent crosstalk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A, 104: 4365-4370. (Pubitemid 47186232)
56. Sharma V, Dixit D, Koul N, Mehta VS, Sen E (2011) Ras regulates interleukin-1beta-induced HIF-1alpha transcriptional activity in glioblastoma. J Mol Med (Berl), 89: 123-136.
57. Sasaki A, Tamura M, Hasegawa M, Ishiuchi S, Hirato J, et al. (1998) Expression of interleukin-1beta mRNA and protein in human gliomas assessed by RT-PCR and immunohistochemistry. J Neuropathol Exp Neurol, 57: 653-663. (Pubitemid 28335054)
58. Iyer A, Zurolo E, Prabowo A, Fluiter K, Spliet WG, et al. (2012) MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PLoS ONE, 7: e44789.
59. Aronica E, Fluiter K, Iyer A, Zurolo E, Vreijling J, et al. (2010) Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci, 31: 1100-1107.
60. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, et al (1994) Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci, 16: 152-161.
61. Liu JS, Zhao ML, Brosnan CF, Lee SC (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol, 158: 2057-2066. (Pubitemid 32545191)
62. Schneemann M, Schoedon G (2002) Species differences in macrophage NO production are important. Nat Immunol, 3: 102. (Pubitemid 34141433)
63. Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol, 40: 599-606.
64. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol, 27: 519-550.
65. Dinarello CA (2010) Why not treat human cancer with interleukin-1 blockade? 10. Cancer Metastasis Rev, 29: 317-329.
66. Kanneganti TD (2010) Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol, 10: 688-698.
67. Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses 17. Nat Immunol, 13: 343-351.
68. Jin C, Flavell RA (2010) Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol, 30: 628-631.
69. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, et al (2009) Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A, 106: 20388-20393.
70. Wen H, Miao EA, Ting JP (2013) Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity, 39: 432-441.
71. Keller M, Ruegg A, Werner S, Beer HD (2008) Active caspase-1 is a regulator of unconventional protein secretion. Cell, 132: 818-831. (Pubitemid 351312798)
72. Yazdi AS, Drexler SK, Tschopp J (2010) The role of the inflammasome in nonmyeloid cells. J Clin Immunol, 30: 623-627.
73. Minkiewicz J, de Rivero Vaccari JP, Keane RW (2013) Human astrocytes express a novel NLRP2 inflammasome. Glia, 61: 1113-1121.
74. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, et al (2012) Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem, 287: 36617-36622.
75. Maruo T, Ichikawa T, Kanzaki H, Inoue S, Kurozumi K, et al (2013) Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology, 33: 264-275.
76. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, et al (2004) Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood, 103: 317-324. (Pubitemid 38029955)
77. Tatenhorst L, Rescher U, Gerke V, Paulus W (2006) Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol Appl Neurobiol, 32: 271-277.
78. Rong Y, Durden DL, Van Meir EG, Brat DJ (2006) 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol, 65: 529-539. (Pubitemid 44288937)
79. John GR, Lee SC, Brosnan CF (2003) Cytokines: powerful regulators of glial cell activation. Neuroscientist, 9: 10-22. (Pubitemid 36139575)
80. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, et al (2006) IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol, 177: 5574-5584. (Pubitemid 44527632)
81. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9: 157-173. (Pubitemid 43357943)
82. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17: 98-110.
83. Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, et al (2007) Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A, 104: 3466-3471. (Pubitemid 46364182)
84. Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, et al (2006) The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis, 24: 128-143. (Pubitemid 44416213)
85. Vezzani A, Friedman A, Dingledine RJ (2013) The role of inflammation in epileptogenesis. Neuropharmacology, 69: 16-24.
86. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, et al (2006) Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A, 103: 11784-11789. (Pubitemid 44182528)
87. John GR, Lee SC, Song X, Rivieccio M, Brosnan CF (2005) IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia, 49: 161-176. (Pubitemid 40188496)